MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease (MediPD)

October 22, 2026 updated by: Claire McEvoy, Queen's University, Belfast

Feasibility Of An Online Self-management Mediterranean Diet Program To Improve Dietary Behaviour And Quality Of Life For People Living With Parkinson's Disease: The MediPD Pilot Randomised Controlled Trial

The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet.

The study will include 120 adults living in the United Kingdom with Parkinson's disease who have access to an internet-enabled device and currently have low adherence to a Mediterranean-style diet. Participants will be randomly assigned to one of two groups. One group will receive access to the MediPD online programme, which includes short educational videos, personalised dietary information, practical resources, goal-setting tools, and online dietetic support. The other group will continue with their usual care and will receive access to MediPD after completing the final study assessment.

Researchers will compare the groups to see whether MediPD improves adherence to a Mediterranean diet after 24 weeks. The study will also examine dietary intake, non-motor symptoms, quality of life, gastrointestinal symptoms, cognitive function, and how acceptable and practical the programme is to use. Assessments will take place at the start of the study, at 12 weeks, and at 24 weeks.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Nicola A Ward, PhD, MSci
  • Phone Number: +44(0)7823368444
  • Email: medipd@qub.ac.uk

Study Contact Backup

  • Name: Sinead O'Hagan, MSc
  • Phone Number: +44(0)7823368444
  • Email: medipd@qub.ac.uk

Study Locations

      • Belfast, United Kingdom, BT12 6BA
        • Recruiting
        • Remote assessments from Centre for Public Health, Queens University Belfast
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Self-reported idiopathic Parkinson's disease
  • Age 18 years or older
  • Community-dwelling and resident in the United Kingdom
  • Access to an internet-enabled device and an active email address
  • Mediterranean Diet Score ≤7/13, indicating low adherence to a Mediterranean diet
  • Proficient in English
  • Able to provide informed consent

Exclusion Criteria:

  • Atypical or secondary parkinsonism
  • Living in an institution
  • Self-reported body mass index <18.5 kg/m²
  • High risk of malnutrition, defined as MUST score ≥2
  • Receiving prescribed nutritional support
  • Significant cognitive impairment, defined as T-CogS ≤21
  • Pregnancy
  • Active inflammatory bowel disease
  • Dysphagia requiring a pureed diet
  • Food allergies that would prevent adherence to a Mediterranean-style diet
  • Following a vegan diet that would prevent adherence to the study's Mediterranean-style dietary intervention.
  • Current participation in another interventional trial
  • Participation in an investigational medicinal product trial within the previous 90 days where this may affect study outcomes or participant burden
  • Previous participation in a My Moves Matter dietary programme.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MediPD Intervention

Participants will receive access to the 12-week MediPD online Mediterranean diet behaviour-change program

MediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provides personalised educational videos, practical resources, self-monitoring tools, and moderated dietetic support. Participants are encouraged to complete at least one module per week, aiming to adopt and maintain Mediterranean-style dietary changes over 24 weeks.

No Intervention: Wait-List Control

Participants will continue to receive their usual care. After completing the final 24-week study assessment, participants in the wait-list control group will be offered access to the MediPD online program for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks
Time Frame: Baseline to 24 weeks

Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.

Baseline to 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 12 Weeks
Time Frame: Baseline to 12 weeks

Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.

Baseline to 12 weeks
Change in self-reported dietary intake using a 24-hour Dietary Recall
Time Frame: Baseline, 12 weeks and 24 weeks.

Dietary intake will be assessed using Intake24, an online 24-hour dietary recall tool. Outcomes will include mean daily intake of energy (kcal/day), foods and macronutrients (g/day and, where appropriate, percentage of energy), and micronutrients (mg or µg/day, as appropriate). Higher values indicate greater intake of food/nutrients.

Baseline, 12 weeks and 24 weeks.
Change in Parkinson's Disease Non-Motor Symptoms using the Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
Time Frame: Baseline, 12 weeks and 24 weeks.

Non-motor symptoms will be assessed using the validated 52-item, rater-administered Movement Disorder Society Non-Motor Rating Scale (MDS-NMS). Total scores range from 0 to 832, with higher scores indicating a greater non-motor symptom burden and a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in reported Gastrointestinal Symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Time Frame: Baseline, 12 weeks and 24 weeks.

Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Items are scored from 1 to 7 and summed to provide a total score ranging from 15 to 105. Higher total scores indicate greater gastrointestinal symptom severity and therefore a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Time Frame: Baseline, 12 weeks and 24 weeks.

Quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39), which covers eight domains. Each domain score is transformed to a 0-100 scale, and the mean of the eight domain scores provides the PDQ-39 Summary Index. Higher Summary Index scores indicate poorer health-related quality of life and therefore a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in cognitive function using TestMyBrain cognitive test battery
Time Frame: Baseline, 12 weeks and 24 weeks.

Cognitive function will be assessed using the TestMyBrain cognitive test battery, comprising Verbal Paired Associates, Visual Paired Associates, Backward Digit Span, Digit Symbol Matching, and Trail Making A and B. Each test score will be converted to a z-score and oriented so that higher scores consistently indicate better performance. The z-scores will be summed to provide an overall cognitive composite score with higher scores indicating better cognitive function.

Baseline, 12 weeks and 24 weeks.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in whole-gut transit time using the Blue Poop Challenge (optional assessment)
Time Frame: Baseline, 12 weeks and 24 weeks.

Consenting participants who opt into this assessment will consume a standardised food-grade blue dye preparation and record the date and time of ingestion and the first appearance of blue colouring in their stool. Whole-gut transit time will be calculated as the elapsed time in hours between ingestion and the first appearance of blue stool. Higher values indicate a longer, slower whole-gut transit time.

Baseline, 12 weeks and 24 weeks.
Intervention acceptability using a study-specific semi-structured qualitative interview
Time Frame: Week 24

Intervention acceptability will be explored through a study-specific semi-structured interview with a purposive sample of approximately 10-15 participants from the MediPD intervention group. Interviews will explore satisfaction and acceptability, relevance and usefulness, engagement, feasibility, platform usability, perceived impact, participant burden, barriers and facilitators, and suggestions for improvement. Interviews will be audio-recorded, transcribed verbatim and analysed qualitatively to identify key themes. This assessment does not generate a numerical score and therefore has no minimum or maximum value.

Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Claire T McEvoy, PhD, Mphil, RD, Queens University Belfast

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2026

Primary Completion (Estimated)

August 30, 2027

Study Completion (Estimated)

February 29, 2028

Study Registration Dates

First Submitted

September 10, 2026

First Submitted That Met QC Criteria

September 17, 2026

First Posted (Actual)

September 24, 2026

Study Record Updates

Last Update Posted (Actual)

October 26, 2026

Last Update Submitted That Met QC Criteria

October 22, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 513675

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.